EXEL News and Press, Exelixis Inc. From 12/07/23

Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing...

2023-12-06 16:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

– STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck – – Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated in these tumors – Exelixis, Inc. (Nasdaq: EXEL...

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 tr...

2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...

2023-11-29 10:45:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – November 29, 2023 – USA News Group –  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the ri...

– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28 at 11:00 am ...

– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% – – Anti-tumor activity was observed in patients who had progressed on prior VEGFR-tyrosine kinase inhibitors,...

2023-11-08 05:19:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly...

2023-11-02 14:45:22 ET Summary Exelixis's Q3 earnings fell short of expectations, with lower-than-anticipated Earnings Per Share and total revenues. The company's pipeline includes innovative therapies and collaborations with partners to revolutionize cancer treatment. Despite...